相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance
Marc Scherlinger et al.
JOINT BONE SPINE (2018)
Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study
S. Gerdes et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
Ross A. McKinnon et al.
BIODRUGS (2018)
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
Paul Declerck et al.
CLINICAL THERAPEUTICS (2018)
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
Hillel P. Cohen et al.
DRUGS (2018)
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France
Jerome Avouac et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
Stanley B. Cohen et al.
ARTHRITIS CARE & RESEARCH (2018)
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
Syed Numan et al.
ADVANCES IN THERAPY (2018)
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study
E. M. H. Schmitz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen et al.
BIODRUGS (2018)
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
IBD To switch or not to switch: that is the biosimilar question
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Pharmacy-mediated substitution of biosimilars - a global survey benchmarking country substitution policies
Hannah Larkin et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2017)
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists
Eline van Overbeeke et al.
BIODRUGS (2017)
Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients
Roberto Minutolo et al.
CLINICAL DRUG INVESTIGATION (2017)
Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis
Won Park et al.
BIODRUGS (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents
Walter Reinisch et al.
BIODRUGS (2017)
Interchangeability of Biosimilars: A European Perspective
Pekka Kurki et al.
BIODRUGS (2017)
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
Shomron Ben-Horin et al.
GUT (2016)
Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars
M. Begona Ruiz-Arguello et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health
Juergen Braun et al.
BIOLOGICALS (2016)
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
Balazs Vezer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
I. Hadjiyianni et al.
DIABETES OBESITY & METABOLISM (2016)
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases
Stefano Gentileschi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
The design of clinical trials to support the switching and alternation of biosimilars
Freddy Faccin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples
Ann Gils et al.
INFLAMMATORY BOWEL DISEASES (2016)
Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)
Thomas Strowitzki et al.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
K. Blackwell et al.
ANNALS OF ONCOLOGY (2015)
Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort
Pascal Juillerat et al.
INFLAMMATORY BOWEL DISEASES (2015)
Biosimilars in rheumatology: current perspectives and lessons learnt
Thomas Doerner et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Therapeutic Efficacy of a Biosimilar Epoetin Alfa in Hemodialysis Patients
Amel Harzallah et al.
SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION (2015)
Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study
Pieter Dylst et al.
PHARMACOECONOMICS (2014)
Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
Partha Sarathi Roy et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2013)
The safety of switching between therapeutic proteins
Hans C. Ebbers et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia
Stefan Krivoshiev et al.
ADVANCES IN THERAPY (2010)
Seven Years of Safety and Efficacy of the Recombinant Human Growth Hormone Omnitrope (R) in the Treatment of Growth Hormone Deficient Children: Results of a Phase III Study
T. Romer et al.
HORMONE RESEARCH (2009)
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
Ulrich Gatzemeier et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
A. Engert et al.
LEUKEMIA & LYMPHOMA (2009)
Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment
Volker Wizemann et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment (vol 24, pg 625, 2008)
V Wizemann et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis
Bak-Leong Goh et al.
NEPHROLOGY (2007)
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
H Schellekens
CLINICAL THERAPEUTICS (2002)
分享论文
